Skip to content

Effectiveness of Saline Water and Lidocaine Injections for the Treatment of Intractable Plantar Keratoma

Effectiveness of Saline Water and Lidocaine Injections for the Treatment of Intractable Plantar Keratoma: A Randomised Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04777227
Enrollment
40
Registered
2021-03-02
Start date
2015-06-07
Completion date
2019-09-15
Last updated
2021-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable Plantar Keratoma

Brief summary

An intractable plantar keratoma (IPK) is a conical thickening of the epidermis' stratum corneum and a common cause of foot pain which can have a significant, detrimental impact on the mobility, quality of life and independence of individuals. Conservative treatments are currently offered to patients with IPK, but they are unsatisfactory since they do not offer a sufficient or permanent reduction of symptoms. The purpose of this study was the evaluation of the feasibility, safety and effectiveness of innovative treatments for intractable plantar keratoma (IPK)

Interventions

2% (20mg/ml) lidocaine solution

DRUGPhysiological water injection

0.9% sterile sodium chloride water

PROCEDUREDebridement

A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.

A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side

Sponsors

Université du Québec à Trois-Rivières
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Having a painful IPK for at least 3 months

Exclusion criteria

* Ongoing pregnancy or breastfeeding * Severe cardiovascular or neurological disease * Immunosuppressed status * Presence of a plantar ulcer * Allergy to lidocaine * History of keloid or hypertrophic scar * Simultaneous painful plantar syndrome unrelated to the presence of an IPK

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in pain (visual analogue scale)Baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 monthsPatients were asked to rate their pain level during the seven previous days on the visual analogue scale (VAS). The VAS is a 10 centimeters line anchored at the beginning by no pain and at the end by worst pain imaginable
Change from baseline in Foot-Function-Index-Revised (FFI-R)Baseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 monthsThe Foot Function Index (FFI) measure the impact of foot pathology on function in terms of pain, disability and activity restriction

Secondary

MeasureTime frameDescription
Change from baseline in size of Intractable plantar keratomaBaseline, 4 weeks, 8 weeks, 12 weeks, 6 months, 12 monthsIPK's length and width was measured with a millimeter scale ruler used in wound care (accuracy ± 0.1 mm). The depth was estimated with a cotton tip applicator technique measured with the same ruler

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026